SUBSCRIBE
SUBSCRIBE
News   Policy

Matrixx Initiatives, Inc. Says FDA Declines to Withdraw Warning Letter

March 9, 2010 | 
1 min read
Reuters -- Matrixx Initiatives Inc said U.S. health regulators declined to withdraw the warning letter on the company's nasal versions of Zicam cold remedy.
Regulatory
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
There is one person missing to complete the team. Recruiting workers. Workforce gaps, job recruitment, and staffing needs. Job vacancy. Talent acquisition campaigns to fill essential roles.
FDA
Busy FDA gives rare disease sector complementary pathways, unanswered questions
June 8, 2026
 · 
8 min read
 · 
Nick Paul Taylor
businessman chooses the path strategy 3d illustration
FDA
Post-Makary, new rare disease framework faces fresh uncertainty
June 8, 2026
 · 
7 min read
 · 
Heather McKenzie
Opinion
The next FDA commissioner must be a champion for gene therapies
June 5, 2026
 · 
4 min read
 · 
Erik Paulsen
Time on the hourglass stopped. Clock on table. Pause in business, collapse.
Regulatory
Stakeholders want Makary’s voucher program paused, call for FDA independence
June 5, 2026
 · 
3 min read
 · 
Tristan Manalac